Advertisement

Rationale for Surfactant Therapy in Pneumonia

  • A. van’t Veen
  • D. Gommers
  • B. Lachmann
Conference paper
  • 96 Downloads
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1997)

Abstract

Pneumonia remains an important cause of morbidity and mortality, despite advances in antimicrobial therapy. Pneumonia causes injury to the terminal alveolo-capillary unit, which is followed by increased alveolar permeability, pulmonary edema and hemorrhage, and may lead to respiratory failure. It has been demonstrated that the pulmonary surfactant system becomes impaired in pneumonia, causing decreased compliance, atelectasis, pulmonary edema, ventilation-perfusion mismatch, intrapulmonary shunting, and an impaired arterial oxygenation [1–3].

References

  1. 1.
    Gommers D, Lachmann B (1993) Surfactant therapy: Does it have a role in adults? Clin Intensive Care 4: 284–295Google Scholar
  2. 2.
    Lachmann B, Gommers D (1993) Is it rational to treat pneumonia with exogenous surfactant? Eur Respir J 6: 1427–1428PubMedGoogle Scholar
  3. 3.
    Brogden KA (1991) Changes in pulmonary surfactant during bacterial pneumonia. Antonie van Leeuwenhoek 59: 215–223PubMedCrossRefGoogle Scholar
  4. 4.
    Lachmann B (1987) The role of pulmonary surfactant in the pathogenesis and therapy of ARDS. In: Vincent JL (ed) Update in intensive care and emergency medicine 1987. Springer-Verlag, Berlin, Heidelberg, pp 123–134Google Scholar
  5. 5.
    Pison U, Max M, Neuendank A, Weissbach S, Pietschmann S (1994) Host defence capacities of pulmonary surfactant: Evidence for `non-surfactant’ functions of the surfactant system. Eur J Clin Invest 24: 586–599Google Scholar
  6. 6.
    Sutnick AI, Soloff LA (1964) Atelectasis with pneumonia. A pathophysiologic study. Ann Intern Med 60: 39–46Google Scholar
  7. 7.
    Holm BA (1992) Surfactant inactivation in Adult Respiratory Distress Syndrome. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: From molecular biology to clinical practice. Elsevier, Amsterdam, pp 665–684Google Scholar
  8. 8.
    Kharasch VS, Sweeney TD, Fredberg J, et al (1991) Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 144: 909–913PubMedCrossRefGoogle Scholar
  9. 9.
    Van ‘t Veen A, Mouton JW, Gommers D, Lachmann B (1997) Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol (In press)Google Scholar
  10. 10.
    Johansson J, Curstedt T, Robertson B (1994) The proteins of the surfactant system. Eur Respir J 7: 372–391PubMedCrossRefGoogle Scholar
  11. 11.
    Van Golde LMG (1995) Potential role of surfactant proteins A and D in innate lung defense against pathogens. Biol Neonate 67 (Suppl 1): 2–17PubMedGoogle Scholar
  12. 12.
    Rider ED (1995) Metabolism of pulmonary surfactant. Sem Resp Crit Care Med 16: 17–28CrossRefGoogle Scholar
  13. 13.
    Guyton AC, Moffat DS, Adair TA (1984) Role of alveolar surface tension in transepithelial movement of fluid. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant. Amsterdam, Elsevier, pp 171–185Google Scholar
  14. 14.
    Lachmann B (1985) Possible function of bronchial surfactant. Eur J Respir Dis 67: 46–61Google Scholar
  15. 15.
    Enhorning G, Duffy LC, Welliver RC (1995) Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 151: 554–556PubMedGoogle Scholar
  16. 16.
    Liau DF, Yin NX, Huang J, Ryan SF (1996) Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Biochim Biophys Acta 1302: 117–128PubMedCrossRefGoogle Scholar
  17. 17.
    Tittball RW (1993) Bacterial phospholipases C. Microbiol Rev 57: 347–366Google Scholar
  18. 18.
    Gilliard N, Heldt GP, Loredo J, et al (1994) Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 93: 2608–2615PubMedCrossRefGoogle Scholar
  19. 19.
    Viuff B, Aasted B, Alexandersen S (1994) Role of alveolar type II cells and of surfactant-associated protein C mRNA levels in the pathogenesis of respiratory distress in mink kits infected with aleutian mink disease parvovirus. J Virol 68: 2720–2725PubMedGoogle Scholar
  20. 20.
    Grimm C, Longmore WJ (1995) Sublethal hydrogen peroxide inhibits alveolar type II cell surfactant phopholipid biosynthetic enzymes. Am J Phys 268: L129–L135Google Scholar
  21. 21.
    Azghani AO, Connely JC, Peterson BT, Gray LD, Collins ML, Johnson AR (1990) Effects of Pseudomonas aeruginosa elastase on alveolar epithelial permeability in guinea pigs. Infect Immun 58: 433–438PubMedGoogle Scholar
  22. 22.
    Stinson SF, Ryan DP, Hertweck MS, Hardy JD, Hwang-Kow SY, Loosli CG (1976) Epithelial and surfactant changes in influenza) pulmonary lesions. Arch Pathol Lab Med 100: 147–153PubMedGoogle Scholar
  23. 23.
    Engen RL, Brown TT (1991) Changes in phospholipids of alveolar lining material in calves after aerosol exposure to bovine herpes virus-1 or parainfluenza-3 virus. Am J Vet Res 52: 675–677PubMedGoogle Scholar
  24. 24.
    Rose M, Lindberg DAB (1968) Effect of pulmonary pathogens on surfactant. Dis Chest 53: 541–544PubMedCrossRefGoogle Scholar
  25. 25.
    Jaeger KE, Kinscher DA, König B, König W (1992) Extracellular lipase of Pseudomonas aeruginosa: Biochemistry and potential role as a virulence factor. In: Hoiby N, Pedersen SS (eds) Cystic Fibrosis, Basic and Clinical Research. Elsevier, Amsterdam, pp 113–119Google Scholar
  26. 26.
    King RJ, Coalson JJ, Seidenfeld JJ, Anzueto AR, Smith DB, Peters JI (1989) 02 and pneumonia-induced lung injury II. Properties of pulmonary surfactant. J Appl Physiol 67: 357–365Google Scholar
  27. 27.
    Coalson JJ, King RI, Winter VT, et al (1989) OZ and pneumonia-induced lung injury I. Pathological and morphometric studies. J Appl Physiol 67: 346–356Google Scholar
  28. 28.
    Sachse K (1989) Changes in the relative concentrations of surfactant phospholipids in young pigs with experimental pneumonia. J Vet Med 36: 385–390CrossRefGoogle Scholar
  29. 29.
    Akino T (1992) Lipid, components of the surfactant system. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: From molecular biology to clinical practice. Elsevier, Amsterdam, pp 19–31Google Scholar
  30. 30.
    Tahvanainen J, Hallman M (1987) Surfactant abnormality after endotoxin-induced lung injury in guinea-pigs. Eur J Respir Dis 71: 250–258PubMedGoogle Scholar
  31. 31.
    Brade H, Brade L, Schade U, et al (1987) Structure, endotoxicity, immunogenicity and antigenicity of bacterial lipopolysaccharides (Endotoxins, 0-Antigens). In: Levin J, Ten Cate JW, Buller HR, et al (eds) Bacterial endotoxins: Pathophysiological effects, clinical significance, and pharmacological controll. Alan R Liss Inc, New York, pp 17–45Google Scholar
  32. 32.
    Kalina M, Blau H, Riklis S, Kravtsov V (1995) Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions. Am J Physiol 268: L144–L151PubMedGoogle Scholar
  33. 33.
    Van Iwaarden JF, Pikaar JC, Storm J, et al (1994) Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J 303: 407–411PubMedGoogle Scholar
  34. 34.
    Kuan SF, Rust K, Crouch E (1992) Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 90: 97–106Google Scholar
  35. 35.
    Lopez A, Albassam M, Yong S, Sharma A, Lillie LE, Prior MG (1987) Profiles of type-II pneumocytes in rats inoculated intratracheally with bacterial lipopolysaccharide. Am J Vet Res 48: 1534–1539PubMedGoogle Scholar
  36. 36.
    Somerson NL, Kontras SB, Pollack JD, Weiss HS (1971) Pulmonary compliance: Alteration during infection. Science 171: 66–68Google Scholar
  37. 37.
    Von Wichert P, Wilke A (1976) Alveolar stability and phospholipid content in normal pig lungs and in pig lungs with Mycoplasma pneumonia. Scand J Respir Dis 57: 25–30PubMedGoogle Scholar
  38. 38.
    Yoneda K, Walzer PD (1981) Mechanisms of pulmonary alveolar injury in experimental Pneumocystis carinii pneumonia in the rat. Br J Exp Path 62: 339–346Google Scholar
  39. 39.
    Sheehan PM, Stokes DC,Yeh YY, Hughes WT (1986) Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 134: 526–531Google Scholar
  40. 40.
    Kernbaum S, Masliah J, Alcindor LG, Bouton C, Christol D (1983) Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia. Br J Exp Path 64: 75–80Google Scholar
  41. 41.
    Phelps DS, Umstead TM, Rose RM, Fishman JA (1996) Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat. Eur Respir J 9: 565–570PubMedCrossRefGoogle Scholar
  42. 42.
    O’Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH (1995) Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 95: 2699–2710PubMedCrossRefGoogle Scholar
  43. 43.
    Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WI (1992) 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 89: 143–149Google Scholar
  44. 44.
    Williams MD, Wright JR, March KL, Martin WJ (1996) Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Respir Cell Mol Biol 14: 232–238PubMedGoogle Scholar
  45. 45.
    Limper AH, Crouch EC, O’Riordan DM, et al (1995) Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages. J Lab Clin Med 126: 416–422PubMedGoogle Scholar
  46. 46.
    Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L (1982) Evidence of lung surfactant abnormality in respiratory failure. Study of broncholaveolar lavage phospholipids, surface activity, phospholipase activity and plasma myoinositol. J Clin Invest 70: 673–683Google Scholar
  47. 47.
    Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H (1984) Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 30: 521–523PubMedGoogle Scholar
  48. 48.
    Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J (1993) Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 147: 653–657PubMedGoogle Scholar
  49. 49.
    Günther A, Siebert C, Schmidt R, et al (1996) Surfactant alterations in severe pneumonia, acute respiratory distress syndrome and cardiogenic lung edema. Am J Respir Crit Care Med 153: 176–184PubMedGoogle Scholar
  50. 50.
    LeVine AM, Lotze A, Stanley S, et al (1996) Surfactant content in children with inflammatory lung disease. Crit Care Med 24: 1062–1067PubMedCrossRefGoogle Scholar
  51. 51.
    Hoffman AGD, Lawrence MG, Ognibene FP, et al (1992) Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 102: 1730–1736PubMedCrossRefGoogle Scholar
  52. 52.
    Escamilla R, Prevost MC, Hermant C, Caratero A, Cariven C, Krempf M (1992) Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients. Chest 101: 1558–1562PubMedCrossRefGoogle Scholar
  53. 53.
    Rose RM, Catalano PJ, Koziel H, Furlong ST (1994) Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 149: 332–338PubMedGoogle Scholar
  54. 54.
    Sternberg RI, Whitsett JA, Hull WM, Baughman RP (1995) Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid. J Lab Clin Med 125: 462–469Google Scholar
  55. 55.
    Phelps DS, Rose RM (1991) Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 43: 1072–1075Google Scholar
  56. 56.
    Meignan M, Guillon JM, Denis M, et al (1990) Increased lung epithelial permeability in HIV-infected patients with isolated cytotoxic T-lymphocytic alveolitis. Am Rev Respir Dis 141: 1241–1248PubMedGoogle Scholar
  57. 57.
    Jobe AH (1993) Pulmonary surfactant therapy. N Engl J Med 328: 861–868PubMedCrossRefGoogle Scholar
  58. 58.
    Johanson WG (1991) Bacterial infection in adult respiratory distress syndrome. In: Zapol M, Lemaire F (eds) Adult Respiratory Distress Syndrome, volume 50. Marcel Dekker, New York, pp 77–89Google Scholar
  59. 59.
    Van Daal GJ, Eijking EP, So KL, et al (1992) Acute respiratory failure during pneumonia induced by sendai virus. Adv Exp Med Biol 316: 319–326PubMedCrossRefGoogle Scholar
  60. 60.
    Van Daal GJ, So KL, Gommers D, et al (1991) Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 72: 589–595PubMedCrossRefGoogle Scholar
  61. 61.
    Eijking EP, Van Daal GJ, Tenbrinck R, et al (1991) Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 17: 475–478PubMedCrossRefGoogle Scholar
  62. 62.
    Van Daal GJ, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B (1992) Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 145: 859–863PubMedGoogle Scholar
  63. 63.
    Van ‘t Veen A, Hendrik ER, Gommers D, Mouton JW, Lachmann B (1994) Surfactant therapy enhances survival of influenza A infected mice. Intensive Care Med 20: S58 (Abst)Google Scholar
  64. 64.
    Tashiro K, Li WZ, Yamada K, Matsumoto Y, Kobayashi T (1995) Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med 23: 149–156.PubMedCrossRefGoogle Scholar
  65. 65.
    Tashiro K, Yamada K, Li WZ, Matsumoto Y, Kobayashi T (1996) Aerosolized and instilled surfactant therapies for acute lung injury caused by intratracheal endotoxin in rats. Crit Care Med 24: 488–494PubMedCrossRefGoogle Scholar
  66. 66.
    Buheitel G, Scharf J, Harms D (1992) Erfahrungen mit der Surfactanttherapie des adulten Atemnotsyndroms ( ARDS ). Monatsschr Kinderheilkd 140: 629–632Google Scholar
  67. 67.
    Harms K, Herting E (1994) Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 61: 348–352PubMedCrossRefGoogle Scholar
  68. 68.
    Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL (1991) Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87: 101–107PubMedGoogle Scholar
  69. 69.
    Wilson DF, Jiao JH, Bauman LA, et al (1996) Calf’s lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 24: 1316–1322CrossRefGoogle Scholar
  70. 70.
    Mikawa K, Maekawa N. Nishina K, Takao Y, Yaku H, Obara H (1993) Selective intrabronchial instillation in a patient with pneumonia: A preliminary report. Eur Respir J 6: 1563–1566Google Scholar
  71. 71.
    Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W (1995) Inhalation of antibiotics incysticfibrosis.Eur Respir J 8: 1594–1604Google Scholar
  72. 72.
    Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F (1994) The quantitative distributon of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 88: 203–211PubMedCrossRefGoogle Scholar
  73. 73.
    Ilowite JS, Gorvay JD, Smaldone GC (1987) Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 136: 1445–1449PubMedCrossRefGoogle Scholar
  74. 74.
    Brain JD, Knudson DE, Sorokin SP, Dabis MA (1976) Pulmonary distribution of particies given by intratracheal instillation or by aerosol inhalation. Environ Res 11: 13–33PubMedCrossRefGoogle Scholar
  75. 75.
    Liu M, Wang L, Li E, Enhorning G (1991) Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 71: 742–748PubMedGoogle Scholar
  76. 76.
    Van ‘t Veen A, Mouton JW, Gommers D, Kluytmans JAJW, Dekkers P, Lachmann B (1995) Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother 39: 329–333CrossRefGoogle Scholar
  77. 77.
    Van ‘t Veen A, Gommers D, Mouton JW, Kluytmans JAJW, Krijt EJ, Lachmann B (1996). Exogenous pulmonary surfactant as a drug delivering agent: Influence of antibiotics on surfactant activity. Br J Pharmacol 118: 595–598Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • A. van’t Veen
  • D. Gommers
  • B. Lachmann

There are no affiliations available

Personalised recommendations